Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 9:08 pm Sale | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | RA CAPITAL MANAGEMENT L.P. | 3,095,136 6.1% | -313,570 (-9.20%) | View |
| 2024-02-14 10:02 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | PRICE T ROWE ASSOCIATES INC | 2,522,704 5.6% | 2,522,704 (New Position) | View |
| 2024-02-13 12:00 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | SUVRETTA CAPITAL MANAGEMENT LLC | 4,774,389 9.99% | 1,363,179 (+39.96%) | View |
| 2024-02-07 07:54 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | ADAGE CAPITAL PARTNERS GP L.L.C. | 4,466,420 9.15% | 2,516,420 (+129.05%) | View |
| 2024-02-06 10:55 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | FRANKLIN RESOURCES INC BEN | 4,640,651 9.5% | 510,514 (+12.36%) | View |
| 2023-12-14 4:04 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | Cormorant Asset Management LP | 6,038,235 12.36% | 6,038,235 (New Position) | View |
| 2023-12-08 5:28 pm Sale | 13D | EYEPOINT PHARMACEUTICALS, INC. EYPT | EW Healthcare Partners L.P. | 2,337,786 5% | -1,312,606 (-35.96%) | View |
| 2023-09-11 11:15 am Sale | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | FRANKLIN RESOURCES INC BEN | 4,130,137 11.8% | -1,644,372 (-28.48%) | View |
| 2023-08-30 5:22 pm Sale | 13D | EYEPOINT PHARMACEUTICALS, INC. EYPT | EW Healthcare Partners L.P. | 3,650,392 10.4% | -38,253,564 (-91.29%) | View |
| 2023-05-01 4:23 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | Cormorant Global Healthcare Master Fund LP | 3,200,000 9.33% | 3,200,000 (New Position) | View |
| 2023-02-14 4:45 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | RA CAPITAL MANAGEMENT L.P. | 3,408,706 9.99% | 1,801,847 (+112.13%) | View |
| 2023-02-13 10:23 am Sale | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | SUVRETTA CAPITAL MANAGEMENT LLC | 3,411,210 9.99% | -70,899 (-2.04%) | View |
| 2023-01-31 11:44 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | FRANKLIN RESOURCES INC BEN | 5,774,509 16.9% | 827,344 (+16.72%) | View |
| 2022-02-11 4:24 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | SUVRETTA CAPITAL MANAGEMENT LLC | 3,482,109 9.99% | 1,886,945 (+118.29%) | View |
| 2022-02-10 09:13 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,950,000 5.75% | 450,000 (+30.00%) | View |
| 2022-02-03 2:12 pm Purchase | 13G | FIGS INC FIGS | FRANKLIN RESOURCES INC BEN | 8,333,476 5.5% | 8,333,476 (New Position) | View |
| 2022-02-03 2:02 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | FRANKLIN RESOURCES INC BEN | 4,947,165 14.6% | 3,533,218 (+249.88%) | View |
| 2021-08-13 4:31 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | RA CAPITAL MANAGEMENT L.P. | 1,606,859 5.6% | 1,606,859 (New Position) | View |
| 2021-07-26 5:21 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | SUVRETTA CAPITAL MANAGEMENT LLC | 1,595,164 5.6% | 1,595,164 (New Position) | View |
| 2021-02-12 4:06 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,500,000 5.23% | 1,500,000 (New Position) | View |